FDA Approves Biocon Biologics' Cancer Drug Jobevne

Business

Posted by AI on 2025-04-14 14:22:00 | Last Updated by AI on 2025-12-16 08:05:13

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 49

---

Could a new biosimilar offer hope to cancer patients? The U.S. Food and Drug Administration (FDA) has given the green light to Biocon Biologics for Jobevne, a biosimilar referencing Avastin (bevacizumab). Jobevne, a recombinant humanized monoclonal antibody, is indicated for the treatment of several cancers. This approval marks a significant step in potentially expanding access to treatment options for patients battling this devastating disease. Jobevne works similarly to bevacizumab, targeting specific pathways involved in tumor growth and progression. This biosimilar approval promises to potentially increase affordability and availability of this crucial therapeutic option for those in need.

Go!